Gene expression profiling identifies clinically relevant subtypes of prostate cancer -- Data Supplement - HTML Page - 04146Table6.htslp -- Proceedings of the National Academy of Sciences

Table 6. Relationship between tumor grade/stage/preoperative serum prostate-specific antigen (PSA) and MUC1/AZGP1 immunostaining

Observed		Low grade		High grade		Total
MUC+		37		8		45
MUC-		105		23		128
Total		142		31		173
expected		Low grade		High grade		Total
MUC1+		37		8		45
MUC1-		105		23		128
Total		142		31		173
P =1 (c ² test)
Observed	Low stage		High stage		Total
MUC1+	23		22		45
MUC1-	74		54		128
Total	97		76		173
Expected	Low stage		High stage		Total
MUC1+	25		20		45
MUC1-	72		56		128
Total	97		76		173
P =0.485 (c ² test)
Observed	PSA<10		PSA 10		Total
MUC1+	30		15		45
MUC1-	84		44		128
total	114		59		173
expected	PSA<10		PSA 10		total
MUC1+	30		15		45
MUC1-	84		44		128
Total	114		59		173
P =1 (c ² test)
Observed	Low grade		High grade		Total
AZGP1+	107		21		128
AZGP1-/w	34		8		42
Total	141		29		170
Expected	Low grade		High grade		Total
AZGP1+	106		22		128
AZGP1-/w	35		7		42
Total	141		29		170
P =0.634 (c ² test)
Observed	Low stage		High stage		Total
AZGP1+	77		51		128
AZGP1-/w	19		23		42
Total	96		74		170
Expected	Low stage		High stage		Total
AZGP1+	72		56		128
AZGP1-/w	24		18		42
total	96		74		170
P =0.072 (c ² test)
Observed	PSA<10		PSA 10		Total
AZGP1+	82		46		128
AZGP1-/w	26		15		41
Total	108		61		169
Expected	PSA<10		PSA 10		Total
AZGP1+	82		46		128
AZGP1-/w	26		15		41
Total	108		61		169
P =1 (c ² test)